199 related articles for article (PubMed ID: 23214471)
1. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
3. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR studies of bicyclic amine series GPR119 agonists.
Sakairi M; Kogami M; Torii M; Kataoka H; Fujieda H; Makino M; Kataoka D; Okamoto R; Miyazawa T; Okabe M; Inoue M; Takahashi N; Harada S; Watanabe N
Bioorg Med Chem Lett; 2012 Aug; 22(15):5123-8. PubMed ID: 22765901
[TBL] [Abstract][Full Text] [Related]
7. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
8. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Apr; 20(7):2369-75. PubMed ID: 22365911
[TBL] [Abstract][Full Text] [Related]
10. Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.
Phillips DP; Gao W; Yang Y; Zhang G; Lerario IK; Lau TL; Jiang J; Wang X; Nguyen DG; Bhat BG; Trotter C; Sullivan H; Welzel G; Landry J; Chen Y; Joseph SB; Li C; Gordon WP; Richmond W; Johnson K; Bretz A; Bursulaya B; Pan S; McNamara P; Seidel HM
J Med Chem; 2014 Apr; 57(8):3263-82. PubMed ID: 24666203
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
13. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological profile of a new selective G protein-coupled receptor 119 agonist; 6-((2-fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one.
Sakairi M; Kogami M; Torii M; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
Chem Pharm Bull (Tokyo); 2012; 60(9):1093-5. PubMed ID: 22976315
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists.
Sakairi M; Kogami M; Torii M; Kuno Y; Ohsawa Y; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
Arzneimittelforschung; 2012 Nov; 62(11):537-44. PubMed ID: 22972470
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
[TBL] [Abstract][Full Text] [Related]
20. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
